Literature DB >> 29947233

MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock.

M Pavkova Goldbergova, J Lipkova, J Fedorko, J Sevcikova, J Parenica, J Spinar, M Masarik, A Vasku.   

Abstract

AIM: Levels of circulating miRNA are considered to be potential biomarkers of acute myocardial infarction and disease progression.
METHODS: In this study, the expression levels of circulating miRNA-1, miRNA-133 and miRNA-124a were investigated in a group of patients with acute myocardial infarction (STEMI) and cardiogenic shock (CS) compared to controls.
RESULTS: During the hospitalization period, miRNA-133 showed a significant up-regulation in the serum of STEMI and CS patients compared to controls, while the expression of miRNA-1 was significantly different only in CS. The expression of miRNA-124 was significantly higher in STEMI and CS. Furthermore, miRNA-1 expression was related to the level of circulating glucose in patients with STEMI. We also found a negative correlation between miRNA-133 and MMP-9 levels. MiRNA-124 expression was significantly related to the level of soluble ST2; the marker correlated to cardiac damage.
CONCLUSION: All selected miRNAs are potential markers of cardiac injury in cardiogenic shock, whereas miRNA-124a and -133 are markers of injury in STEMI. MiRNA-1 expression is related to circulating glucose in STEMI. None of miRNAs could be correlated to the extent of injury, progress of the disease, or prognosis of patient outcome. Therefore, the levels of circulating miRNA have no potential for becoming a biomarker of myocardial damage and as such would bring no further benefit compared to current markers (Tab. 4, Fig. 1, Ref. 47).

Entities:  

Keywords:  STEMI; cardiogenic shock prognosis.; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29947233     DOI: 10.4149/BLL_2018_064

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  7 in total

Review 1.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

2.  Marathon-Induced Cardiac Strain as Model for the Evaluation of Diagnostic microRNAs for Acute Myocardial Infarction.

Authors:  Omid Shirvani Samani; Johannes Scherr; Elham Kayvanpour; Jan Haas; David H Lehmann; Weng-Tein Gi; Karen S Frese; Rouven Nietsch; Tobias Fehlmann; Steffi Sandke; Tanja Weis; Andreas Keller; Hugo A Katus; Martin Halle; Norbert Frey; Benjamin Meder; Farbod Sedaghat-Hamedani
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

3.  Activation of PTEN/P13K/AKT Signaling Pathway by miRNA-124-3p-Loaded Nanoparticles to Regulate Oxidative Stress Attenuates Cardiomyocyte Regulation and Myocardial Injury.

Authors:  Yuan Cheng; Qing He; Na Li; Mengdi Luo
Journal:  Oxid Med Cell Longev       Date:  2022-10-11       Impact factor: 7.310

4.  The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis.

Authors:  Yehuda Wexler; Udi Nussinovitch
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600

Review 5.  Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection.

Authors:  Branislav Kura; Barbora Kalocayova; Yvan Devaux; Monika Bartekova
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923

6.  Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock.

Authors:  Mikko Hänninen; Toni Jäntti; Heli Tolppanen; Heli Segersvärd; Tuukka Tarvasmäki; Johan Lassus; Mélanie Vausort; Yvan Devaux; Alessandro Sionis; Ilkka Tikkanen; Veli-Pekka Harjola; Päivi Lakkisto
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

7.  Exosomal miR-218-5p/miR-363-3p from Endothelial Progenitor Cells Ameliorate Myocardial Infarction by Targeting the p53/JMY Signaling Pathway.

Authors:  Xiao Ke; Rongfeng Yang; Fang Wu; Xing Wang; Jiawen Liang; Xun Hu; Chengheng Hu
Journal:  Oxid Med Cell Longev       Date:  2021-07-16       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.